The treatment landscape for prostate cancer has undergone a seismic shift, particularly regarding the management of high-risk biochemical recurrence (BCR). For years, clinicians operated under a philosophy of "watchful waiting" or reactive intervention once metastatic disease was radiographically confirmed. However, the Phase III EMBARK trial (NCT02319837) has challenged this traditional dogma, providing robust, level-1 evidence that earlier, proactive systemic intervention significantly improves long-term outcomes.
In a recent expert discussion, principal investigators Dr. Stephen J. Freedland (Cedars-Sinai Medical Center) and Dr. Neal Shore (START Cancer Research Center) synthesized the landmark findings of the EMBARK study. They examined how the integration of enzalutamide, both in combination with leuprolide and as monotherapy, is redefining the standard of care for patients with high-risk BCR.
The Evolution of the EMBARK Trial: A Chronology of Success
The EMBARK trial was designed to address a critical void in prostate cancer management: how to treat patients who show signs of recurrence—specifically those with a prostate-specific antigen (PSA) doubling time of nine months or less—but who lack visible metastasis on conventional imaging.
The Study Design
The trial enrolled patients with rigorously demonstrated BCR following primary therapy (radical prostatectomy, radiation, or both). Participants were randomized into three cohorts:
- Combination Arm: Enzalutamide plus leuprolide.
- Monotherapy Arm: Enzalutamide alone.
- Control Arm: Leuprolide alone.
A unique aspect of the EMBARK protocol was the "treatment holiday" or deintensification cycle. Patients who achieved a PSA nadir of <0.2 ng/mL after 37 weeks of treatment were permitted to suspend therapy, resuming only upon meeting pre-specified PSA progression thresholds.
Landmark Milestones
The study’s trajectory has been marked by a series of high-impact presentations and publications. Over the past two years, the investigators have presented data at major global forums, including the American Urological Association (AUA) and the European Society of Medical Oncology (ESMO). These presentations provided the foundation for FDA and EMA regulatory approvals, shifting the clinical paradigm for nonmetastatic, castrate-sensitive prostate cancer.
Supporting Data: Survival and Quality of Life
The data emerging from EMBARK are not merely statistically significant; they are clinically transformative. The trial met its primary endpoint of metastasis-free survival (MFS), demonstrating that enzalutamide-based regimens drastically delay the progression to metastatic disease.
Overall Survival Advantage
Perhaps the most compelling evidence presented by Dr. Freedland and Dr. Shore is the overall survival (OS) benefit. The combination of enzalutamide and leuprolide showed a 40% reduction in the risk of death compared to leuprolide alone. "It is hard to imagine having a conversation with a patient saying, ‘We have a treatment that could reduce your risk of death by 40%, or we can just wait,’" Dr. Freedland noted.
Maintenance of Quality of Life
A common concern with systemic androgen deprivation therapy (ADT) is the impact on patient-reported outcomes (PROs). Data from EMBARK confirmed that health-related quality of life was maintained across both the combination and monotherapy arms. This suggests that the aggressive treatment of high-risk BCR does not come at the cost of day-to-day patient well-being, provided that side effects are managed proactively.
Addressing the "Real-World" Clinical Dilemmas
Beyond the primary data, the investigators addressed the "gray zones" that clinicians face daily.
The Role of PSMA-PET Imaging
The rise of PSMA-PET imaging has complicated the definition of "nonmetastatic" disease. Many patients who appear "clean" on conventional CT or bone scans show lesions on PSMA-PET. Dr. Freedland introduced the term "CIN" (Conventional Imaging-Negative) to describe these patients. He argued that because enzalutamide has proven survival benefits in the EMBARK population, the discovery of micro-metastases via PET should not lead to treatment delay. Instead, he advocates for an aggressive, multi-modal approach: systemic therapy combined with metastasis-directed radiation where appropriate.
The Art of Intermittent Therapy
The concept of "true intermittent" therapy remains a hot topic. While EMBARK only protocolized one off-treatment cycle, the investigators suggested that for patients who achieve a rapid, deep nadir, subsequent cycles of deintensification are reasonable. "If you have a patient that has a really nice reduction very rapidly on reinitiation, after discussion, I think it’s reasonable to say let’s do this again," said Dr. Freedland.
Management of Side Effects
For patients on enzalutamide monotherapy, the primary side effect is breast-related tenderness or enlargement. Dr. Shore emphasized that clinicians should move away from reactive treatment and toward prevention. He discussed the use of low-dose tamoxifen (10 mg taken periodically) as a successful strategy to mitigate these effects, a practice supported by findings published in European Urology Focus.
Implications for Clinical Practice
The EMBARK study has effectively dismantled the nihilism that once surrounded the treatment of PSA-only recurrence. The key takeaways for the oncology community are:
- Aggression is Justified: Waiting for macroscopic, symptomatic metastatic disease is no longer a defensible strategy when a 40% survival benefit is on the table.
- Individualization is Paramount: While the combination of enzalutamide and leuprolide is the gold standard for survival, enzalutamide monotherapy offers a viable alternative for patients prioritized on maintaining libido and sexual function.
- The Multidisciplinary Flywheel: Effective management now requires a robust team—urological oncologists, medical oncologists, radiation oncologists, and cardiologists—to manage the holistic needs of the patient, from bone health to cardiovascular risk.
The Future of BCR Management
As the field moves forward, the focus will shift toward better integration of these therapies with emerging imaging technologies and potentially more frequent cycles of treatment suspension. "If you don’t do it at the first sign of high-risk BCR, you are never going to catch up," Dr. Freedland warned.
The EMBARK trial has provided the data; the next challenge for the medical community is the translation of these findings into consistent, high-quality, and patient-centered care. By moving beyond the initial fear of treatment side effects and embracing the proven survival advantages of early intervention, clinicians can significantly improve the longevity and quality of life for their patients.
Disclosure Statement: The original research and podcast discussion were supported by funding from Pfizer Inc. and Astellas Pharma Inc. Dr. Freedland and Dr. Shore have served as consultants for multiple pharmaceutical entities, including those involved in the development of enzalutamide.
About the Author
